Crossmark

Fong’s Score in the Era of Modern Perioperative Chemotherapy for Metastatic Colorectal Cancer: A Post Hoc Analysis of the GERCOR-MIROX Phase III Trial

Crossref DOI link: https://doi.org/10.1245/s10434-019-07976-7

Published Online: 2019-10-22

Published Print: 2020-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Makhloufi, Samira

Turpin, Anthony

el Amrani, Mehdi

André, Thierry

Truant, Stéphanie

Bachet, Jean-Baptiste

Vernerey, Dewi

Hebbar, Mohamed
License Information

Text and Data Mining valid from 2019-10-22

Version of Record valid from 2019-10-22
More Information

Article History

Received: 12 June 2019

First Online: 22 October 2019

Disclosure

: Thierry Andre: Honorary or consultant or advisory board: Astra Zeneca, Amgen, BMS, MSD Oncology, HalioDx, Roche, Ventana, Sevier, Chugai, and Yacult; Jean-Baptiste Bachet : Consultancy and/or honorary from Amgen, Astra Zeneca, Bayer, Merck Serono, Pierre Fabre, Roche, Sanofi, and Servier; The other authors have no conflicts of interest to declare.

Document is current

Any future updates will be listed below